Skip to main content

Table 3 Representative incremental cost-effectiveness ratio for each drug indication in increasing order

From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs

Drug

Indications

ICER ( in US$) *

Nilotinib

Chronic myeloid leukemia, chronic phase: 1st-line

17,314

Imatinib

Gastrointestinal stromal tumor: Adjuvant therapy

29,591

Cetuximab

Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid

42,026

Pemetrexed

NSCLC (for non-squamous histology): 1st line with cisplatin

44,451

Lenalidomide

Multiple myeloma: 1st-line

68,941

Pemetrexed

NSCLC: Maintenance treatment

73,978

Sorafenib

Liver cancer: 1st line

82,792

Sunitinib

Renal cell carcinoma: 1st line

85,572

Lapatinib

Breast cancer with HER2 overexpression: 2nd line with capecitabine

93,496

Bevacizumab

Colorectal cancer: with irinotecan, fluorouracil, and leucovorin

98,937

Bevacizumab

Colorectal cancer: with oxaliplatin, fluorouracil, and folinic acid

110,967

Dasatinib

Chronic myeloid leukemia, chronic phase: 1st-line

118,050

Cetuximab

Colorectal cancer: with irinotecan

121,528

Temsirolimus

Renal cell carcinoma: 1st-line for poor prognosis patients

128,595

Bevacizumab

Renal cell carcinoma: 1st line with interferon-α

131,070

Crizotinib

NSCLC (ALK fusion positive): 2nd line (vs. docetaxel)

158,133

Bevacizumab

NSCLC: 1st line with platinum-based chemotherapy

196,000

Cetuximab

Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy

261,767

Erlotinib

Pancreatic cancer: 1st line with gemcitabine

430,000

  1. ICER, Incremental Cost Effectiveness Ratio; NSCLC, non-small cell lung cancer.
  2. *Most ICER values except two indications were retrieved from the National Institute for Health and Clinical Excellence in United Kingdom (costs are expressed in US dollars; £1 equals $1.574 (as of January 29, 2013)).
  3. This value was from the Pharmaceutical Benefits Advisory Committee in Australia. (Canadian $1 equals US $0.98) http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-03/pbac-psd-bevacizumab-march11.
  4. This value was from Miksad RA et al. J Clin Oncol 25:4506–7; author reply 4508, 2007.